This webinar will address the critical global disparities in the standard of care for precision medicine, focusing on access to and reimbursement of Next Generation Sequencing (NGS) for identifying molecular targets. These disparities have a profound impact on clinical trial operations and patient access to innovative treatments.
Key discussion points will include:
- Challenges in standardizing precision oncology globally.
- The role of clinical trials in increasing access to NGS.
- Operational and technical strategies to overcome standard of care challenges.
Panelists:
- Dr. David Thomas, Director of the Centre for Molecular Oncology, UNSW, and Chief Strategy and Science Officer at Omico, Australia.
- Dr. Steven Yip, Medical Oncology Lead, Precision Oncology & Experimental Therapeutics, Tom Baker Cancer Centre, Canada.
- Prof. Chia-Chi Lin, Director of Phase I Center at National Taiwan University Hospital.
- Dr. Chun-Hui Lee, Clinical Assistant Professor, Department of Oncology, National Cheng Kung University.
- Vishal Doshi, CEO, AUM Biosciences, Singapore.
- Nelson Lin, Senior Project Manager, Novotech.
- Moderator: Courtney Thornely, Senior Therapeutic Strategy Manager, Novotech.
Explore the operational and strategic considerations shaping precision oncology trials, from pre-screening challenges to the role of technology in improving trial efficiency and outcomes.
Reserve your spot to gain actionable insights from leading experts in precision oncology and discuss the evolving global standard of care for cancer patients.